clinical trial · NCT07764237
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults
ModernaTX, Inc.·phase1·not yet recruiting·n = 375
Respiratory Syncytial Virus (RSV)Human Metapneuomovirus (hMPV)mRNA-1365 (Profile 2)mRNA-1345 (Profile 1)mRNA-1345 (Profile 3)
brief summary
The main objective of this trial is to evaluate the safety, reactogenicity, and immunogenicity of study interventions across intervention groups
started
Aug 16, 2026
primary completion
Jul 20, 2027
completion
Jul 20, 2027
last updated
Aug 13, 2026
official title
A Phase 1, Randomized, Open-label Staggered Dose-escalation and Observer-blind Expansion Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Multicomponent Vaccine mRNA-1365 (Profile 2 [RSV and hMPV]) in Healthy Adults ≥60 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol